CDSCO Panel Approves Novartis Healthcare's Protocol Amendment to study Iptacopan
New Delhi: The Subject Expert Committee (SEC), functional under the Central Drug Standard Control Organization (CDSCO), has approved the protocol amendment proposal presented by Novartis Healthcare for Iptacopan (LNP023) study.
This came after the firm presented protocol amendment version 04 dated 30 Nov 2023, protocol no. CLNP023B12001B. This is an open-label, non-randomized extension study to evaluate the long-term efficacy, safety, and tolerability of iptacopan (LNP023) in C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis.
Glomerulopathy refers to any disease of the glomeruli, the tiny filters in the kidneys. Idiopathic immune-complex-membranoproliferative glomerulonephritis (IC-MPGN) is a specific type of glomerular disease where immune complexes and complement proteins are deposited in the kidney, potentially due to overactivation of the alternative complement pathway.
Iptacopan is a member of the class of indoles that is 1H-indole substituted by [(2S,4S)-2-(4-carboxyphenyl)-4-ethoxypiperidin-1-yl]methyl, methoxy, and methyl groups at positions 4, 5, and 6, respectively. It is a potent inhibitor of complement factor B with potential immunomodulatory activity. It has a role as a complement factor B inhibitor and an immunomodulator.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.